/ Suven Life Sciences secures patent in Macau, Israel, S Korea ~ Ways2Capital|Stock Tips|Stock Market Tips|Intraday Stock Tips|Stock Trading Tips|NSE BSE Tips

Monday, 10 July 2017

Suven Life Sciences Ltd informed on Monday that it has secured one product patent from Israel, one from Macau and one from South Korea.

The product patents correspond to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and these patents are valid through CY 2032.

The granted claims of the patents are from the mechanism of action include the class of selective H3 inverse agonist compounds and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, attention deficient hyperactivity disorder (ADHD),  Huntington’s disease, major depressive disorder (MDD), Parkinson and schizophrenia.  

For Quick Trial – 8962000225 ✔
or mail us here: info@ways2capital.com
✆ - 0731-6626222 | Toll Free - 1800-3010-2007 
Give a Missed Call for Free Trial - 09699997717